Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACLX |
---|---|---|
09:32 ET | 7526 | 53.34 |
09:34 ET | 2725 | 53.2 |
09:36 ET | 1800 | 52.76 |
09:38 ET | 677 | 53.045 |
09:39 ET | 600 | 53.32 |
09:41 ET | 716 | 53.28 |
09:43 ET | 200 | 53.21 |
09:45 ET | 1800 | 53.31 |
09:48 ET | 600 | 53.47 |
09:50 ET | 1700 | 53.35 |
09:52 ET | 1069 | 53.33 |
09:54 ET | 2100 | 53.4 |
09:56 ET | 500 | 53.34 |
09:57 ET | 2500 | 53.67 |
09:59 ET | 1367 | 53.574 |
10:01 ET | 2572 | 53.77 |
10:03 ET | 100 | 53.85 |
10:06 ET | 1099 | 54.11 |
10:08 ET | 3130 | 54.085 |
10:10 ET | 2200 | 54.045 |
10:12 ET | 2882 | 53.79 |
10:14 ET | 1800 | 53.76 |
10:15 ET | 3006 | 53.555 |
10:17 ET | 2102 | 53.43 |
10:19 ET | 2361 | 53.4 |
10:21 ET | 8638 | 53.46 |
10:24 ET | 3404 | 53.41 |
10:26 ET | 1500 | 53.435 |
10:28 ET | 2823 | 53.55 |
10:30 ET | 4627 | 53.51 |
10:32 ET | 5480 | 53.415 |
10:33 ET | 3100 | 53.34 |
10:35 ET | 1978 | 53.5 |
10:37 ET | 500 | 53.42 |
10:39 ET | 6110 | 53.58 |
10:42 ET | 3200 | 53.54 |
10:44 ET | 3451 | 53.455 |
10:46 ET | 1733 | 53.47 |
10:48 ET | 1200 | 53.62 |
10:50 ET | 800 | 53.63 |
10:51 ET | 800 | 53.7 |
10:53 ET | 800 | 53.8 |
10:55 ET | 1100 | 53.84 |
10:57 ET | 1400 | 53.79 |
11:00 ET | 4000 | 53.5 |
11:02 ET | 600 | 53.595 |
11:04 ET | 4453 | 53.62 |
11:06 ET | 700 | 53.6 |
11:08 ET | 500 | 53.63 |
11:09 ET | 200 | 53.6 |
11:11 ET | 8275 | 53.57 |
11:13 ET | 800 | 53.5625 |
11:15 ET | 700 | 53.5 |
11:18 ET | 1200 | 53.665 |
11:20 ET | 200 | 53.76 |
11:22 ET | 600 | 53.79 |
11:24 ET | 36830 | 53.68 |
11:26 ET | 4911 | 53.72 |
11:27 ET | 300 | 53.78 |
11:29 ET | 1220 | 53.77 |
11:31 ET | 500 | 53.74 |
11:33 ET | 600 | 53.81 |
11:36 ET | 3301 | 53.72 |
11:38 ET | 400 | 53.87 |
11:40 ET | 300 | 53.86 |
11:42 ET | 700 | 53.82 |
11:44 ET | 800 | 53.945 |
11:45 ET | 6701 | 53.84 |
11:47 ET | 300 | 53.925 |
11:49 ET | 1400 | 54.1 |
11:51 ET | 300 | 54.24 |
11:54 ET | 900 | 54.19 |
11:56 ET | 700 | 54.39 |
11:58 ET | 408 | 54.17 |
12:00 ET | 2000 | 54.34 |
12:02 ET | 700 | 54.36 |
12:03 ET | 2500 | 54.29 |
12:05 ET | 4315 | 54.31 |
12:07 ET | 800 | 54.285 |
12:09 ET | 100 | 54.28 |
12:12 ET | 3300 | 54.205 |
12:14 ET | 400 | 54.2 |
12:16 ET | 2413 | 54 |
12:18 ET | 1900 | 54.17 |
12:20 ET | 600 | 54.34 |
12:21 ET | 1100 | 54.33 |
12:23 ET | 100 | 54.335 |
12:25 ET | 555 | 54.24 |
12:27 ET | 1134 | 54.3 |
12:30 ET | 100 | 54.185 |
12:32 ET | 600 | 54.19 |
12:34 ET | 300 | 54.22 |
12:36 ET | 500 | 54.075 |
12:38 ET | 1226 | 54.095 |
12:39 ET | 200 | 54.06 |
12:41 ET | 1607 | 54.15 |
12:43 ET | 1600 | 54.07 |
12:45 ET | 200 | 54.085 |
12:48 ET | 200 | 54.04 |
12:50 ET | 600 | 53.82 |
12:52 ET | 400 | 53.93 |
12:54 ET | 1700 | 53.95 |
12:56 ET | 141 | 54.03 |
12:57 ET | 295 | 53.96 |
12:59 ET | 700 | 53.955 |
01:03 ET | 300 | 53.86 |
01:06 ET | 1807 | 53.68 |
01:08 ET | 1502 | 53.66 |
01:10 ET | 300 | 53.655 |
01:14 ET | 1900 | 53.56 |
01:15 ET | 1500 | 53.6 |
01:17 ET | 400 | 53.61 |
01:19 ET | 354 | 53.605 |
01:21 ET | 2036 | 53.78 |
01:24 ET | 100 | 53.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcellx Inc | 2.9B | -51.7x | --- |
Rhythm Pharmaceuticals Inc | 2.6B | -8.6x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.6x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.3x | --- |
SpringWorks Therapeutics Inc | 2.7B | -6.9x | --- |
Agios Pharmaceuticals Inc | 2.5B | -6.9x | --- |
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
---|---|
Revenue (TTM) | $131.7M |
Shares Outstanding | 53.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.04 |
Book Value | $9.28 |
P/E Ratio | -51.7x |
Price/Sales (TTM) | 21.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -57.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.